https://www.optimumcomms.com/wp-content/uploads/2026/07/AC-Immune-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-11 12:03:422026-08-11 12:03:42AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
https://www.optimumcomms.com/wp-content/uploads/2026/07/AC-Immune-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-11 12:03:422026-08-11 12:03:42AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-11 08:44:392026-08-11 08:44:39Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine
https://www.optimumcomms.com/wp-content/uploads/2025/04/AstronauTx_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-10 09:23:552026-08-10 09:24:48AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration
https://www.optimumcomms.com/wp-content/uploads/2026/07/AC-Immune-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-08-05 12:03:052026-08-05 12:03:05AC Immune First Half 2026 Financial and Corporate Update
https://www.optimumcomms.com/wp-content/uploads/2026/07/simris-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-28 08:41:202026-07-28 08:44:22Simris Group Appoints Biotechnology Expert Dr. Tiffany J. Vora as Strategic Advisor
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-28 08:33:132026-07-28 08:33:13Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-24 14:07:402026-07-24 14:07:40NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
https://www.optimumcomms.com/wp-content/uploads/2026/07/ReBio-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-22 15:15:252026-07-22 15:15:25ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-22 06:06:482026-07-22 06:06:48Hansa Biopharma Reports Second Quarter and First Half Year 2026 Financial Results
https://www.optimumcomms.com/wp-content/uploads/2026/03/Template_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-21 12:05:362026-07-21 12:05:36R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-21 08:56:002026-07-21 08:56:00Poolbeg Pharma plc – Notice of Allowance received for POLB 001 Cancer Immunotherapy-induced CRS patent in Israel
https://www.optimumcomms.com/wp-content/uploads/2025/09/AMS.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-20 12:53:002026-07-20 12:53:00Advanced Medical Solutions Group plc – Half Year 2026 Trading Update
https://www.optimumcomms.com/wp-content/uploads/2026/07/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-17 08:34:212026-07-17 08:36:15Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
https://www.optimumcomms.com/wp-content/uploads/2026/07/simris-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-15 08:36:232026-07-15 08:36:47Simris Group AB Appoints ADC Expert Professor Andreas Pahl as Chief Executive Officer of its Subsidiary Simris Biologics GmbH
https://www.optimumcomms.com/wp-content/uploads/2026/07/Genopo-logo-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-14 14:08:462026-07-14 14:11:21Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company
https://www.optimumcomms.com/wp-content/uploads/2026/01/Nucleome_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-14 09:32:362026-07-14 09:32:36Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC TechnologyWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
